The new “Continuity of Care” measure has good intentions but comes with severe penalties and without necessary checks and ...

Shimy, and Tim Beyers debate whether the hundreds of billions presently committed to AI infrastructure will pay off for ...

Next, the editorials insist that China is profoundly resilient. They note risks, including American protectionism and weak ...

First, the short term. If peace is to endure over the coming months, the new Gazan leadership will need legitimacy within ...

His remarks come amid a heated political debate after Kharge’s letter triggered sharp criticism from the BJP, which accused ...

Tesla has surprised the market by launching cheaper versions of its best-selling models, the Model 3 Standard and Model Y Standard, both with a discount of at least $5,000 compared ...

A baroness and British diplomat visited an Oxford school to see pupils debate world issues.

Both the Tivoli Model One BT and the Ruark R1 prove size doesn’t matter—at least when it comes to sound that refuses to be ...

A panel that studied Alberta's post-secondary institutions has released its recommendations, which include replacing the ...

The controversy erupted when a tech-savvy commentator directly challenged Sridhar Vembu on the Arattai's handling of ...

Builder.ai entered 2025 claiming to revolutionise AI-powered app development, but was exposed as a massive fraud.

If you have been staring at CRISPR Therapeutics stock lately, wondering whether it is time to buy, hold, or rethink your position, you are far from alone. Over the past week, the stock has surged 16.1 ...